Oligomerix wins $1.9m NIH grant to advance Alzheimer’s drug safety trials (opens in new tab)

Oligomerix has received a $1.9 million Phase II Small Business Innovation Research Fast-Track award from the National Institute on Aging of the National Institutes of Health to fund nonclinical safety studies required to support a planned Phase 1b study of OLX-07010 in Alzheimer’s patients. The award will support a 13-week dosing study in a non-rodent […] The post appeared first on <a href="